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license (http://creativecreases due to expandingmarkets for health care services demanded by aging populations and/or peo-
ple with a wide range of chronic disorders-disabilities, is a complex and formidable challenge with
many facets. Current projections predict marked increases in the demand for health driven by both
the exponential climb in the prevalence of chronic disabilities and the increases in the absolute
numbers of people in need of some form of health care. Thus, the looming predicament for the eco-
nomics of health care systems worldwide mandates the formulation of a strategic goal to foster sig-
nificant expansion of global R&D efforts to discover and develop wide-ranging interventions to delay
and/or prevent the onset of chronic disabling conditions. The rationale for adopting such a tactical
objective is based on the premise that the costs and prevalence of chronic disabling conditions will
be reduced by half even if a modest delay of 5 years in the onset of disability is obtained by a highly
focused multinational research initiative. Because of the recent history of many failures in drug trials,
the central thesis of this paper is to argue for the exploration-adoption of novel mechanistic ideas,
theories, and paradigms for developing wide range and/or types of interventions. Although the
primary focus of our discussion has been on biological approaches to therapy, we recognize the
importance of emerging knowledge on nonpharmacological interventions and their potential impact
in reducing health care costs. Although we may not find a drug to cure or prevent dementia for a long
time, research is starting to demonstrate the potential contributes of nonpharmacological interven-
tions toward the economics of health care in terms of rehabilitation, promoting autonomy, and poten-
tial to delay institutionalization, thus promoting healthy aging and reductions in the cost of care.
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R&D efforts to discover and develop wide-ranging interven-
tions to delay and/or prevent the onset of chronic disabling
conditions. The rationale for adopting such a tactical objec-
tive is based on the premise that the costs and prevalence of
chronic disabling conditions will be reduced by half even if a
modest delay of 5 years in the onset of disability is obtained
by a highly focused multinational research initiative [1,2].
Because of the recent history of many failures in drug tri-
als, the central thesis of this paper is to argue for the
exploration-adoption of novel mechanistic ideas, theories,
and paradigms for developing wide range and/or types of in-
terventions. Although the primary focus of our discussion
has been on biological approaches to therapy, we recognize
the importance of emerging knowledge on nonpharmacolog-
ical interventions and their potential impact in reducing
health care costs. Although we may not find a drug to cure
or prevent dementia for a long time, research is starting to
demonstrate the potential contributes of nonpharmacologi-
cal interventions toward the economics of health care in
terms of rehabilitation, promoting autonomy, and potential
to delay institutionalization, thus promoting healthy aging
and reductions in the cost of care.
An international strategic research-planning workshop
(The meeting was convened by the Network Center for
Biomedical Research in Neurodegenerative Disease
(CIBERNED), CIEN Foundation, and Reina Sofia Founda-
tion, Madrid, Spain.) was organized on September 21–23,
2016 in Malaga, Spain to consider some forward-looking
ideas for such an international cooperative research effort.
The present paper outlines the challenges and recommenda-
tions for future research on a broad spectrumof interventions.2. Why focus on Alzheimer’s disease?
Chronic brain disorders, such as Alzheimer’s disease
(AD), dementia, and other neurodegenerative disorders,
constitute some of the most significant contributors to the
quandary of health care systems worldwide. These neurolog-
ical conditions that lead to prolonged functional impair-
ments (i.e., diminish individuals’ capacity to carry out
activities of daily living) exemplify a unique class of disabil-
ities because of their profound economic impact and psycho-
social ramifications. Progressive functional impairments of
cognition, motor skills, and emotion, which are the most
common clinical features of these unremitting brain condi-
tions, ultimately lead to total reliance on labor-intense care
to sustain life. AD has been proposed as the perfect proto-
type for this wide range of disorders and a pragmatic starting
point (a proxy) for attacking the larger and more complex
problem of chronic brain disorders [1,2].
Remarkable advances have been made in recent years in
understanding the biological basis of neurodegeneration.
Subsequently, it has become increasingly accepted that de-
laying the onset of disabling symptoms of neurodegenerative
conditions is an attainable goal. Hence, developing R&D ca-pacity for innovations that will reduce the prevalence of
chronic brain disorders is an urgent need. However, several
scientific impediments should be first surmounted. Among
these barriers, crucial challenges are (1) changing current
paradigms for the development of novel treatments and (2)
improving the discovery of more effective therapeutic
targets.
In the general arena of stimulating new thinking and
fostering new perspectives, the important topics of modifi-
able risk factors and disease mechanism were the focus of
discussion at theMalaga meeting. The present paper outlines
the perspectives and recommendations of some key opinion
leaders in the field of dementia research participating in the
event. Here, we discuss some of the important obstacles to
develop effective therapies as well as future direction for
research and opportunities for therapy development.3. New perspectives on risks factors and disease
mechanisms
Alzheimer’s syndrome is a polygenic and heterogeneous
disorder with multiple patterns of expression. The late-onset
sporadic form (SAD) is the most prevalent AD type, with the
early-onset familial type (FAD) being responsible of only
about 1% of the cases. Although both types follow a similar
pathological and biochemical course, it is highly debated
whether they should be considered as a single pathophysio-
logical entity. Therefore, it would be of the highest impor-
tance to have a single general mechanistic hypothesis that
could harmonize all biochemical and neuropathological fea-
tures of both AD types.
In this context, a large part of the deliberations at Malaga
were devoted to the pathogenic mechanisms underlying the
neurodegenerative process. It has been a quarter of a century
since the amyloid cascade hypothesis proposed that the pres-
ence of amyloid beta (Ab) peptide aggregates is the
first cause in the development of AD pathogenesis, whereas
neurofibrillary pathology and neuronal cell loss are
consequences of that primary cause [3]. Although FAD-
based genetic evidence has provided strong support to the
hypothesis, clinical trials targeting the amyloid pathway on
SAD patients have shown disappointingly negative results
in recent years, leading to discussions about whether the am-
yloid cascade hypothesis might not be valid for all SAD
cases [4,5].
Discovery of mutations in the APP, PSEN1, and PSEN2
genes causing FAD has been instrumental in the current un-
derstanding of the biochemical pathways leading to neuro-
degeneration and dementia. Furthermore, the findings from
genome-wide association studies (GWASs) and massive par-
allel sequencing have come to underscore the multifactorial
nature of AD. Notwithstanding, translating genetic findings
into functional molecular mechanisms biologically relevant
in disease pathogenesis and therapy design still remains a
challenge.
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sion have been proposed, with Ab pathology developing
early and neurofibrillary pathology and neuronal death tak-
ing place later [6]. The first stagewould be a clinically silent,
symptom-free condition but may be the right moment for
Ab-targeted treatment. Indeed, it has been proposed that at
later stages of the disease, once tau pathology has developed,
anti-amyloid therapies might not be as effective [7].
With regards to SAD cases, there is growing evidence
suggesting that the appearance of pathology is due to the
interplay of a combination of factors that include potentially
modifiable risk factors based on lifestyle, such as education,
socioeconomic position, physical activity, cardiovascular or
metabolic profile [8–10], as shown in Table 1. In addition,
although some genetic risk factors have been identified
[11], aging remains by far the main risk factor for SAD, a
risk that could be associated with some specific molecular
changes such as for instance calcium homeostasis [12,13],
that could affect synaptic function or neuronal health and
facilitate the development of the disease.
The relative importance of any one of these factors in
increasing the risk or influencing the expression of the dis-
ease differs from one individual to another in SAD, whereas
for FAD, the presence of a specific mutation results in higher
similarities among the patients [11]. Thus, some special fea-
tures of SAD lead to the recognition of Alzheimer’s as a syn-
drome rather than a disease, collectively characterized by a
group of symptoms, often consisting of mixed or overlap-
ping pathologies. Alzheimer’s syndrome is heterogeneous
with respect to factors such as age of onset of symptoms, pat-
terns or mix of clinical symptoms, neuropathology, bio-
markers, response to treatment, risk factors, and genetics.
Furthermore, it is now evident that the gradual molecular
changes in the brain leading to the syndrome start decades
before any symptoms can be detected.
It is important to highlight that cognition is not confined
to memory but involves the full range of cognitive functions
such as language, perception, creativity, and social activity.
Thus, the concept of a cognitive footprint has been recently
put forward [9] by which a range of activities throughout the
life span will have an effect (either positive or negative) on
cognition that could be associated with specific footprints
of the disease.
Martin Rossor has been a strong advocate for the value of
stratification, namely the effort to explore and classify the
different types of dementia as well as the various forms ofTable 1
Risk factors for sporadic Alzheimer’s disease
Nonmodifiable factors Aging
Genetic factors
Modifiable factors Life style factors (physical activity, diet,
education)
Cardiovascular profile (stroke, lipid metabolism)
Metabolic syndrome (diabetes, hypertension,
obesity)
Depressionthe concept of AD, such as the differences between SAD,
young onset Alzheimer’s disease, and autosomal-dominant
familial AD. (Presentations at theMalaga meeting can be ac-
cessed through the following link: www.youtube.com/
watch?v5u2AGVQ-XeDA.) Rossor has also argued for
the value of considering cognitive impairment in its totality
and to the many different factors, which can contribute to
cognitive impairment, many of which alone may not result
in severe cognitive impairment or dementia but are likely
to influence the phenotypic expression of AD. These factors
may influence cognition at different times of the life course
but have the potential to impact adversely on the presence of
AD late in life. Over the life course, these factors will
include epigenetic ones via ancestral environment, preg-
nancy and perinatal factors, education, poverty, pollution,
and the effects of systemic illness and medication among
others. All of these factors can influence cognitive capital
at both an individual level and group level. Policies and in-
dividual actions that enhance cognitive capital, that is, those
with positive as opposed to negative cognitive footprints,
might be anticipated to mitigate the effects of AD late in life.
Thus, there could be modifiable and nonmodifiable risk
factors, the first ones mostly related to life style and the sec-
ond ones to genetic factors. Implementation of an increasing
number of case-control studies and the upcoming of large-
scale GWASs have brought us a mounting list of genetic
risk factors linked to common genetic variants that have
been associated with sporadic AD, the ε4 allele of the apoli-
poprotein E (APOE) being the most relevant genetic factor
for SAD [14].
Cedazo-Minguez has been gathering evidence that sup-
ports his notion that impairment in cholesterol metabolism
is important in the mechanisms behind neurodegenerative
processes, particularly in AD [15,16]. (Presentations at the
Malaga meeting can be accessed through the following
link: www.youtube.com/watch?v5u2AGVQ-XeDA.)
The importance of cholesterol metabolism in modulating
AD risk and pathogenesis was initially suggested by clinical
and epidemiological studies [17,18] and has been confirmed
by more recent genetic and basic research studies [15]. As
already mentioned, the presence of the APOE ε4 allele is
the strongest known genetic risk factor for sporadic AD.
ApoE is the major transporter of cholesterol in the CNS,
and individuals carrying APOE ε4 (15–20% of the popula-
tion) have a higher probability to develop AD and several
other neurodegenerative disorders, compared to carriers of
other apoE isoforms [15]. Because of the strong association
of APOE ε4 with AD, extensive efforts have been made to
investigate its relation with Ab pathology (reviewed in
[19]). Individuals carrying the APOE ε4 allele showed
increased plaque deposition. In addition, in animal models
of brain Ab-amyloidosis, the pathology was increased with
the insertion of the human apoE4 isoform. Lipid-coupled
apoE4 binds Ab with lower affinity than lipid-coupled
apoE3 suggesting that apoE4 lipoproteins are less efficient
in mediating Ab clearance. Moreover, glial cells carrying
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apoE4 (reviewed in [19]).
As the main role of apoE in the CNS is to carry and
deliver cholesterol from glial cells to neurons, it is suggested
that a reduced capacity of apoE4 in transporting cholesterol
would have consequences for synaptogenesis and repair
mechanisms, and thus in disease progression. Indeed, the
results from recent GWASs are in agreement with this
hypothesis, as other genes related to cholesterol synthesis,
transport, uptake, or metabolism (i.e., ABCA7, ABCA1,
CLU, CYP46A1) have been found to be associated with
AD (Fig. 1). All these evidences imply that manipulation
of brain cholesterol metabolism has therapeutic potential
for AD. Improving the lack of function of apoE4 in choles-
terol transport and neutralizing its negative effects for Ab
pathology are necessary efforts to counteract the role of
apoE4 to neurodegenerative processes.
Another aspect of the role of cholesterol in AD pathogen-
esis is the influence of the peripheral cholesterol on the dis-
ease mechanisms. As cholesterol is unable to pass the blood
brain barrier (BBB), it remains puzzling to understand its
relation to the accumulation of Ab or hyperphosphorylated
tau in the brain. Unlike cholesterol, its side-chain oxidized
forms known as oxysterols are able to traverse the BBB
from both directions [20]. High levels of circulating choles-
terol are associated with increased production of 27-
hydroxycholesterol (27OH), a peripherally produced and
BBB permeable oxysterol. Thus, hypercholesterolemia is
associated with augmented blood-to-brain flux of 27OH
[20]. Indeed, increased levels of 27OH were found in brains
and cerebrospinal fluid from AD patients [21]. Cedazo-Min-
guez’s group and others have contributed to deciphering the
role of 27OH, in relation to neurodegeneration and AD [20],
including a plausible link between the increased levels of
this oxysterol, hypertension, and AD-related neurodegener-
ation [22,23]. Furthermore, new functions of 27OH related
to memory formation and consolidation were also
discovered, and treatment with dietary cholesterol orFig. 1. List of genes involved in familial (mutations) and sporadic (risk fac-
tors) Alzheimer’s disease [26,43,44]. Abbreviations: FAD, familial
Alzheimer’s disease; SAD, sporadic Alzheimer’s disease.excessive 27OH was shown to reduce the levels of the
“memory protein” activity-regulated cytoskeleton-associ-
ated protein (Arc) in vivo and in vitro [24].
The molecular mechanisms leading to AD pathology are
certainly complex and include dysfunctions in several pro-
cesses such as oxidative stress, protein misfolding, mitochon-
drial dysfunction, neuroinflammation, and alterations in
signal transduction and neurotransmission [25]. Ongoing
studies, using novel transgenic modified mice, are designed
to investigate the mechanistic contribution of altered choles-
terol metabolism and 27OH on the neuropathological mecha-
nism leading to AD. The preliminary data presented at the
meeting reinforced the idea that disruptions in cholesterol ho-
meostasis are active contributors to AD pathogenesis. The
notion of a heterogeneous etiology of AD is gaining accep-
tance in the scientific community, and increasing evidence
suggests that alterations in the metabolism of cholesterol
could be one of the driving forces toward AD [26]. The iden-
tification of patient subtypes, with homogenous etiology and
prognosis, will result in more accurate treatments in the future
[27]. It is likely that different subtypes, resulting from
different causing pathways, should be treated differently. In
addition, the identification of novel biomarkers for subtyping
ADwill open possibilities for precise medicinal interventions.
Following this rationale, the classification of individuals with
high 27OH and the characterization of the toxic, proneurode-
generative effects of this oxysterol would be important to stop
or to reduce the risk for AD in those individuals.
Besides APOE, which presents a strong association with
the disease, the rest of the gene factors mentioned previously
have moderate or low degrees of association [28,29]. These
genetic factors related to the risk of appearance of the
disease can be linked to a few biochemical pathways such
as lipid metabolism [30], immune system, endocytosis
[31], or calcium homeostasis [32]. In addition, a specific
feature for SAD could be the failure of adult neurogenesis,
at the dentate gyrus.
The potential role of deficient adult neurogenesis in mem-
ory loss has also been studied by Avila’s group using two
distinct mouse models overexpressing glycogen synthase ki-
nase (GSK-3b) under two different promoters, one being ex-
pressed early and the other one late during the neurogenesis
process in the dentate gyrus. The results show that overex-
pressing GSK-3b at different time points during adult neuro-
genesis has opposite consequences on memory. An increase
in GSK-3b levels at earlier stages facilitates the generation
of newborn neurons, whereas at later stages, it leads to an
aberrant neuronal morphology and function resulting in
impaired neurogenesis. Changes in microglia population
were also observed, together with an increase in the level
of aging-related proteins such as eotaxin, which could be
toxic for neuronal precursor cells [33]. Potential implica-
tions for the use of kinase inhibitors were also discussed.
However, all the genetic factors together can only account
for a fraction of the AD risk, so that rare variants and
epistatic gene interactions should be considered when trying
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Nevertheless, despite the identification of these genetic loci
associated with AD, a large proportion of the genetic compo-
nent of the disorder remains to be elucidated. Hence, other
mechanisms must exist to at least partially explain this
missing heritability, such as for instance epistasis, rare vari-
ants, or the presence of somatic mutations.
Somatic genomic events, which occur in only one gener-
ation or one group of cells and which may affect specific
genes, are known to be associated with various disorders,
particularly cancer. It has been estimated that approximately
80% of all types of cancers arise from somatic mutations
[34,35]. It is a commonly held view that the initial step in
many tumors is mediated by DNA damage and mutations,
which trigger activation of proto-oncogenes, inactivation
of tumor-suppressor genes, and tumor progression and
metastasis. Identifying genes that are mutated in cancer
has been crucial not only for understanding the pathogenesis
but also for designing novel therapeutic agents [36,37].
The so-called somatic mutation theory of aging states that
the accumulation of mutations in the somatic cells genetic
material as a function of time results in decreased cellular
function. Thus, it has been proposed that a combination of
lifestyle and genetics may lead to the occurrence of brain so-
matic mutations that could also play a part in the “dark mat-
ter” of AD because a significant proportion of the
conceivable genetic defects linked to the development of
SAD remains unexplained. This missing defect has been
named as the “dark matter” in an effort to explain the
missing heritability by means of GWAs analysis using
DNA from lymphocytes [38].
Systematic studies searching for somatic brain mutations
in SAD or other neurological diseases have not been per-
formed until very recently. Whole-exome sequencing has
been used to investigate the presence of single-nucleotide
polymorphisms, single-nucleotide variations (SNVs), and
mutations specific to brain genomic DNA in SAD, and absent
in the blood genome of the same subjects, finding a remark-
ably unusual number of brain-specific SNVs in SAD patients
[39,40]. These variations may arise from somatic mutations
that take place during development or during adulthood.
Another study showed that the appearance of SNVs is not
random throughout the genome but that there are a higher
proportion of those variants at specific chromosomes
[41,42]. Additional recent studies have reported brain-
specific retrotransposon insertions [43,44] and somatic copy
number variations in control human neurons [45], which tak-
ing all together emphasize the variability in the brain genome,
and indicate that genetic mosaicism and brain-specific genetic
variations may contribute to the pathogenesis of SAD.
Thus, different triggering events in FAD could result in a
different initial development of pathological mechanisms
(e.g., mutations in APP or PSEN1 genes could trigger initial
steps in the pathological cascade). However, as pathology
progresses further, common features might start appearing.
Something similar may take place in SAD that could havedifferent initial causes but will end with a common patholog-
ical signature.4. Crucial challenges for disease mechanism–based
interventions
Despite remarkable advances in understanding the neuro-
biology underlying AD, during the last three decades,
numerous attempts to develop effective disease-modifying
therapies have failed to demonstrate clinical efficacy. The
reasons for these successive failures to develop treatment
for AD have been the topic of extensive deliberations, where
a variety of potential contributors or plausible answers for
these disappointing results have been considered. However,
these explanations do not adequately account for the poor
outcomes of most efficacy trials.
The failures in therapy development have begun to reinforce
the growing recognition that there are major gaps in our under-
standing of the neurodegenerative process in AD. An important
contributing factor to this dilemmamight be the [nearly] exclu-
sive reliance of current therapy development paradigm on a
single [or limited] presumption about pathobiology of the
disease. It is now clear that dementia-AD is a complex entity
that includes a variable genetic signature potentially accounting
for a significant portion of disease risk [46-47]. The failure to
account for these complex relationships between the clinical
features and the biological phenotypes of the disease may
underlie or explain the reason for the failures of clinical
studies on treatments.
The prospect of a “complex disease” model for dementia-
AD will require re-evaluating current drug development par-
adigms, which rely on a set or hierarchy of assumptions
derived from reductionist approach to explain the underlying
biological of neurodegenerative process. This line of
reasoning, which infers a single pathogenic pathway to all
forms of AD (for instance, late-onset sporadic AD vs.
early-onset familial AD), has led to acceptance of a linear
or a unitary pathogenic pathway. This potentially erroneous
assumption of a single pathogenic pathway, without due
consideration for the complex interactions among the multi-
ple molecular mechanisms involved in the path to dementia,
may account for the selection or focus on inappropriate ther-
apeutic targets in the failed clinical trials.
Thus, to attain the goal of a quantum shift in prospective par-
adigms for therapy development, the grand challenge for the
field is to reexamine all major ideas-theories on the origins,
that is, underling neurobiology, of neurodegeneration and start
formulation-adopting alternative or novel models of dementia,
based on complexity sciences and systems theory [48].5. Novel conceptual models of dementia
One example for an alternative conceptual model for de-
mentia could be formulated on the premise of considering
AD as a syndrome, rather than a disease. This designation
of a syndrome explicitly implies that the disorder consists
M. Medina et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 3 (2017) 571-578576of different patterns of behavioral or clinical features and thus
argues for the occurrence of several interconnected neural net-
works. In such a complex model, the discrete neural networks
that underlie the various clinical features, for example,
depression, agitation, cognitive decline, and so on could over-
lap and coexist. This scenario will require exploring several
therapeutic targets in parallel for improving a series of symp-
toms beyond cognition, such as depression, agitation, sleep,
movement disorder, and so on. This model is based on the
premise that the array of clinical features, which characterize
the different forms of the disorder, that is, dementia-AD,
reflect a systems failure in the various components of a com-
plex neural network. Thus, clinical symptoms of the syn-
drome would be the result of progressive dysfunctions in
various interconnected networks within a system, for instance
the cholinergic system [49].
The “systems failure model” does not rely on a unitary
mechanism to trigger the neurodegenerative process but
rather it requires the dissection of complex interactions
among several essential functional elements of a system.
Thus, the novel paradigm for therapy development entails
the analysis of constitutive components of the system to un-
derstand the interactions among major parts of the system to
identify strategies (interventions improving or maintaining
the overall performance of the system). Such a model, a
“system” built on the integration of a hierarchy of function
components with increasing levels of complexity, would
allow exploration of suitable targets for interventions at
various levels of the system such as a cell signaling biochem-
ical pathway, a neuron, a neural circuit or network, a brain
structure, or a physiological system. The future challenge
for this conceptual framework is to figure out the intricate in-
teractions among various processes needed for sustaining
optimal system performance. The development of effective
interventions, based on a systems model, will require new
research to understand better the interplay within various
brain environments, genetic variants, and ensuing pheno-
types. We need to account for the evolution and temporality
of upstream and downstream pathological alterations to
explain heterogeneity of the disorder, that is, the possibility
that different individuals experience brain failure for distinct
reasons and through different pathways.
Presently, there is no single unifying theory that accounts
for all of thewell-established facts about the neurobiology of
dementia-AD. There is an urgent need to critically reassess
all major ideas to develop novel conceptual models of de-
mentia by creating a solid framework for diversifying and
refining drug discovery and development undertakings. It
is only through such redirection of R&D efforts we can
expect to improve the prospects for more effective and
safe interventions.6. Remaining challenges and unanswered questions
To move forward with the long-term global objective of
reducing health care costs by developing interventions todelay or prevent the onset of disability, thus enable or
prolong independent function of people with chronic disor-
ders, such as dementia-AD, we must address several
challenges. Here, we discuss the major obstacles that must
be surmounted and the crucial scientific questions that
must be tackled.6.1. What are the obstacles that must be surmounted in the
formulation of a prospective comprehensive theory on
neurodegenerative disorders, for example, dementia-AD
syndrome?
Presently, there is no single unifying theory that accounts
for all the well-established facts about the neurobiology of
dementia-AD. There is an urgent need to critically reassess
all major ideas to develop novel conceptual models of
dementia by creating a solid framework for diversifying and
refining drug discovery and development. It is only through
such redirection of R&D efforts we can expect to improve
the prospects for more effective and safe interventions.6.2. What are the serial [temporal] and causal
[mechanistic] links or relationships among the major ideas
on putative etiological and risk factors?
Although emerging data are beginning to show potential
linkages among some of the major hypotheses on the origins
of dementia (e.g., ideas on the role of amyloid, tau, inflam-
mation, calcium, cholinergic, metabolic, etc.), these putative
relationships have not been validated. Thus, to untangle the
complex interactions among these molecular events, we
must develop novel models or modeling systems (e.g., in sil-
ico simulations) for systematic explorations and validation
of these associations among these biochemical signaling
systems or paths.6.3. What are [if any] the common threads for risk factors
in Alzheimer’s syndrome?
Presently, the mechanistic relationships among the
various risk factors are not known, and the various hypothe-
ses about these common mechanisms have not been vali-
dated. This question remains as one of the important
challenges for future R&D on preventive therapies.6.4. What are, if any, the risk factors that can accurately
detect the presence of the “disease” or predict with great
precision the pending onset of symptoms in asymptomatic
individuals, rather than in cohort or populations?
One of the critical challenges for the ongoing research on
modifiable and unalterable risk factors is to discover and vali-
date (by longitudinal prospective studies) a risk factor or com-
bination of risk factors that can accurately detect the “disease”
in the very early stages; ideally in asymptomatic or preclinical
stages. The knowledge and the technology to enable this early
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the development and testing of prevention therapies.6.5. What are the challenges associated to the strategies
for mitigation and monitoring these risks?
The current ongoing studies, in the EU and US, on various
aspects of risk factors are not specifically designed to validate
the prognostic potential or predictive precision of any individ-
ual or group of biomarkers or risk factors. The particular re-
quirements for such a study, which include very large
numbers of well-characterized subject, long duration (several
years) longitudinal study design, coordination across multiple
sites/countries, high cost, and so on, make the planning, the
launch, and execution of such a massive project difficult chal-
lenges.6.6. What are the links among such neurodegenerative
diseases as Alzheimer’s disease, Parkinson’s disease,
dementia with Lewy bodies, amyotrophic lateral sclerosis,
and frontotemporal dementia?
The precise nature of the molecular links among several
neurodegenerative disorders is not known; however, there
are several speculative ideas that need to be validated by
further studies, such as the notion of a “final common path”
mediated by gradual-progressive loss of synaptic connectiv-
ity [13]. The ongoing efforts to re-evaluate all major theories
with an eye toward developing a common framework for
comparing major ideas on etiology are intended to establish
cross-disease pathways underlying common molecular
mechanisms in neurodegenerative disorders [48,50–52].Acknowledgments
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